Back to the peptide atlas
Tissue & repairPeptideNot FDA/EMA approved

Thymosin beta-4

Actin-regulating peptide

Also known as: Tβ4 · TB4

No account · this device only

The essentials at a glance

Classification
Peptide · Tissue & repair
Mechanism
Endogenous actin-binding peptide
Evidence
Preclinical
Status
Not FDA/EMA approved

Regulates cell migration and tissue processes; therapeutic applications remain largely experimental.

Distinction: Thymosin beta-4 is the endogenous protein from which the shorter fragment TB-500 is derived.

Prohibited or covered under WADA rules in competitive sport.

Evidence strengthPreclinical

Available data come mostly from animal or cell models; robust human efficacy and safety data are lacking.

Not FDA/EMA approved: No FDA- or EMA-approved medicinal product; efficacy and safety are not established.

Research questions

Mechanism: Thymosin beta-4

01

Actin-regulating peptide

This concerns effects on the cell-skeleton protein actin, which gives cells their shape and enables movement, like an internal scaffold. Researchers measure cell migration and wound closure in cell culture models.

02

Cell migration peptide

This studies how a peptide influences the migration of cells toward an injury site, similar to workers rushing to a construction site. Speed and extent of cell migration are measured in lab models.

03

Tissue repair models

Researchers use controlled wound or injury models in cells or animals to study how quickly and completely tissue heals after damage. Measures typically include wound size over time and markers of new tissue formation, similar to photographing a cut each day to see how fast it closes.

Simple example

Endogenous repair signal

Think of it like an internal alarm signal that prompts the body toward existing repair processes, similar to a call placed to the body's own repair crew.

Triggering a signal does not automatically mean a predictable or sufficient repair response across the whole organism.

Community themes

How communities discuss it

Personal experience reports and vendor marketing from communities are not scientific proof of efficacy.

Wound healing anecdotes

People report perceived faster healing of injuries or tendon problems after using certain peptides, usually without a control group or objective measurement. Such individual reports do not establish actual efficacy or safety.

Recovery and injury forums

Personal recovery times after sports injuries while using different repair peptides are compared, often based on subjective pain scales. Such individual courses are influenced by many other factors and do not prove efficacy.

Anti-aging forums

Combinations of growth-axis, mitochondrial, and skin peptides are compared here with the goal of influencing visible or felt signs of ageing, often documented personally over years. Anecdotes and vendor advertising about slowed ageing are not scientific proof.

Evidence boundary

Therapeutic applications remain largely experimental and are not clinically confirmed.

No peptide sales or individual recommendations. A separately labelled community area documents third-party protocol claims without medically endorsing them.

Primary sources

Regulators, trial registries and scientific databases support the classification and carry more weight than vendor or community claims.